HC Wainwright Has Positive Estimate for KALV Q4 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities research analysts at HC Wainwright raised their Q4 2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report issued on Tuesday, July 8th. HC Wainwright analyst A. Fein now forecasts that the specialty pharmaceutical company will earn ($0.35) per share for the quarter, up from their previous forecast of ($0.84). HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals' FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.62 EPS, FY2029 earnings at $3.37 EPS and FY2030 earnings at $4.08 EPS.

A number of other research analysts have also recently commented on KALV. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Jones Trading reissued a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Leerink Partners lifted their price objective on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Finally, JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Tuesday, July 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals Stock Down 6.4%

Shares of KALV stock traded down $0.99 during mid-day trading on Thursday, reaching $14.52. The company's stock had a trading volume of 2,085,829 shares, compared to its average volume of 572,060. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $16.32. The firm has a market capitalization of $725.27 million, a PE ratio of -3.93 and a beta of -0.04. The company's 50 day simple moving average is $12.57 and its 200-day simple moving average is $11.26.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter in the previous year, the business earned ($1.07) EPS.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently modified their holdings of KALV. Goldman Sachs Group Inc. raised its stake in KalVista Pharmaceuticals by 3.7% during the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after buying an additional 12,263 shares in the last quarter. Rhumbline Advisers raised its position in shares of KalVista Pharmaceuticals by 3.4% during the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock valued at $611,000 after acquiring an additional 1,762 shares in the last quarter. Woodline Partners LP lifted its stake in KalVista Pharmaceuticals by 25.5% during the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after purchasing an additional 329,068 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in KalVista Pharmaceuticals in the first quarter worth $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after purchasing an additional 2,939 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the sale, the chief executive officer owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the sale, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,878 shares of company stock worth $723,617. 10.50% of the stock is currently owned by corporate insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).